This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Will Anavex Life Sciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Anavex Life Sciences Corp.
Anavex Life Sciences (AVXL) Stock Moves -0.38%: What You Should Know
by Zacks Equity Research
In the latest trading session, Anavex Life Sciences (AVXL) closed at $2.62, marking a -0.38% move from the previous day.
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA
by Zacks Equity Research
Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.
Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AVXL) Outperforming Other Medical Stocks This Year?
Implied Volatility Surging for Anavex (AVXL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Anavex (AVXL) stock based on the movements in the options market lately.
Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status
by Zacks Equity Research
The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
by Zacks Equity Research
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
Anavex Life Sciences (AVXL) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.
Will Anavex Life Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Anavex Life Sciences.
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy
by Zacks Equity Research
Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Anavex Life Sciences (AVXL) a New Strong Buy Stock
by Zacks Equity Research
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) is focused on Consumer Self Care Americas segment. It remains to be seen if this benefits the company's results in the soon-to-be reported quarter.
Can Pharmacy Services Drive CVS Health's (CVS) Q2 Earnings?
by Zacks Equity Research
Akin to the previous quarters, net new business and the steady uptake of Maintenance Choice programs are likely to bolster CVS Health's (CVS) PBM business in Q2.
Can All-Line Growth Aid CVS Health's (CVS) Earnings in Q2?
by Zacks Equity Research
Within the Health Care Benefits segment, CVS Health (CVS) expects the government programs to go from strength to strength on the back of Medicare growth and major Medicaid wins.
What's in Store for Cardinal Health (CAH) in Q4 Earnings?
by Zacks Equity Research
Better-than-expected performance at Pharmaceutical and Medical segments are likely to aid Cardinal Health's (CAH) in Q4 earnings.
Henry Schein (HSIC) to Post Q2 Earnings: A Beat in Store?
by Zacks Equity Research
Henry Schein (HSIC) is working diligently to grow in the field of digital dentistry, globally.
Can Patient Wins Aid GW Pharmaceuticals (GWPH) Q2 Earnings?
by Zacks Equity Research
GW Pharmaceuticals (GWPH) is witnessing a solid new patient recruitment for Epidolex and a huge number of physicians are recommending the same in their prescriptions.
Can Bruker (BRKR) Q2 Earnings See BioSpin's Growth Revival?
by Zacks Equity Research
Bruker (BRKR) expects BioSpin to bode well for better organic growth in Q2.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
5 Biomedical Stocks That Are Expected To Surge
by Jeffrey Hymen
With the promise of regulatory reform on the horizon, investors have been excited about the biomedical space throughout the year. If you want to add some to your portfolio, check out these 5 biomedical stocks that are primed to skyrocket here.
The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics
Zacks.com featured highlights: Anavex Life Sciences, Kinross Gold, LightPath Technologies, MFA Financial and Student Transportation
by Zacks Equity Research
Zacks.com featured highlights: Anavex Life Sciences, Kinross Gold, LightPath Technologies, MFA Financial and Student Transportation